The ATS/ERS/JRS/ALAT Statement “IPF by HRCT” could Predict Acute Exacerbation of Interstitial Lung Disease in Non-small Cell Lung Cancer

Asai, Nobuhiro; Katsuda, Eisuke; Hamanaka, Rie; Kosaka, Kenshi; Matsubara, Ayako; Nakagawa, Masaki; Tanaka, Hiroyuki; Yokoe, Norihito; Takahashi, A; Yamaguchi, Etsuro; Kubo, Akihito

doi:10.5301/tj.5000574

Cited by 15 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preexisting ILD was the consistent risk factor for developing fibrosis in our study, as was found in previous reports . Specifically, the UIP pattern or a possible UIP pattern visible in the CT scan was proven to be the prognostic factor for developing severe CIP or acute exacerbation of ILD . We found that moderate to severe emphysema also increased the risk of developing fibrosis and severe fibrosis over 11% in extent as well.…”

Section: Discussionsupporting

confidence: 89%

Significance of baseline computed tomography assessment for predicting the pulmonary fibrosis during the course of chemotherapy‐induced pneumonitis

Han

Lee

et al. 2019

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Background The purpose of our study is to evaluate risk factors for the development of pulmonary fibrosis in the baseline computed tomography (CT) during the course of chemotherapy‐induced pneumonitis (CIP). Methods We retrospectively identified 80 cases of CIP by clinical, radiological, and pathological findings. When fibrosis developed during the follow‐up, the extent of pulmonary fibrosis was evaluated at final follow‐up CT in terms of a 5% volumetric score for six zones. Univariate and multivariate analyses were performed to identify the clinical and radiological risk factors for the development of fibrosis and severe fibrosis over 11% in extent. Results Fibrosis occurred in 26 of the 80 total patients (32.5%) during a mean 5.6 months of follow up. Risk factors for developing fibrosis were revealed as preexisting interstitial lung disease (ILD) and moderate to severe emphysema in multivariate analysis (OR = 10.12, 95% CI = 2.35‐43.66, and OR = 12.85, 95% CI = 2.81‐58.82, respectively). Risk factors for developing severe fibrosis over 11% in extent were revealed as a moderate to severe emphysema (OR = 5.78, 95% CI = 1.07‐31.26) in multivariate analysis. Conclusions Moderate to severe emphysema as well as preexisting ILD visible on baseline CT are risk factors for developing pulmonary fibrosis in the course of CIP. Thin‐section CT may be helpful to predict the risk of pulmonary fibrosis before administering chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 89%

Significance of baseline computed tomography assessment for predicting the pulmonary fibrosis during the course of chemotherapy‐induced pneumonitis

Han

Lee

et al. 2019

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…Although chemotherapy is often used for patients with NSCLC and ILD, evidence for improved prognosis with chemotherapy is lacking. Several studies found that the incidence rate of acute exacerbation (AE) of ILD ranged between 5% and 35% in patients with NSCLC and ILD undergoing chemotherapy . We recently reported that mortality after AE in these patients was 20% .…”

Section: Introductionmentioning

confidence: 99%

Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non‐small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A UIP pattern on CT was reported to be a risk factor for chemotherapy-induced acute exacerbation of ILD (1,11,14). Another report demonstrated that lower forced vital capacity is a risk factor, but a UIP pattern is not (4).…”

Section: Discussionmentioning

confidence: 99%

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

Yasuda

Nomizo

Ozasa

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Lung cancer with preexisting interstitial lung disease (ILD) is difficult to treat due to the risk of acute exacerbation of ILD. Nanoparticle albumin-bound (nab-) paclitaxel improves the overall response rate and reduces neuropathy more efficiently compared with conventional solvent-based (sb-) paclitaxel in patients with advanced non-small-cell lung cancer. However, it is not known whether the risk of acute exacerbation of ILD with nab-paclitaxel is higher compared with that with sb-paclitaxel. Advanced lung cancer patients with ILD treated with nab-paclitaxel (n=14) or sb-paclitaxel (n=14) were retrospectively reviewed. Acute exacerbation of ILD developed in 1/14 patients (7.7%) receiving nab-paclitaxel and 3/14 patients (21.4%) receiving sb-paclitaxel; the difference was not statistically significant. To the best of our knowledge, this is the first study to compare the incidence of acute exacerbation of ILD with nab-paclitaxel with that of sb-paclitaxel in patients with advanced lung cancer with preexisting ILD. The results of the present study support conducting a prospective clinical trial to confirm the clinical benefit of this agent.

show abstract

The ATS/ERS/JRS/ALAT Statement “IPF by HRCT” could Predict Acute Exacerbation of Interstitial Lung Disease in Non-small Cell Lung Cancer

Abstract: ILD with a UIP pattern or possible UIP pattern by the classification could be a risk factor for AE-ILD in NSCLC patients with ILD.

Cited by 15 publications

References 34 publications

Significance of baseline computed tomography assessment for predicting the pulmonary fibrosis during the course of chemotherapy‐induced pneumonitis

Significance of baseline computed tomography assessment for predicting the pulmonary fibrosis during the course of chemotherapy‐induced pneumonitis

Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non‐small cell lung cancer

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease

Contact Info

Product

Resources

About